Category : Search result: pharmaceutical competition


Evexia Lifecare Share Price Rises 3% on High Volumes

Evexia Lifecare share price gained over 3% with heavy trading volumes. Discover the Q2 FY26 results showing a sharp profit fall and the stock's long-term decline. Read analysis before investing.

Hvax Technologies H1 FY26 Income Jumps 35%

Hvax Technologies announces impressive 35% growth in total income for H1 FY26, reaching ₹5.95 crore. The company shows strong financial performance with significant profit improvements.

India Urges Russia to Fast-Track Export Approvals

India requests Russia to expedite approvals for Indian exporters in marine, pharmaceutical sectors during Moscow talks. Bilateral trade targets $100B by 2030. Key discussions ahead of Putin's December visit.

Lincoln Pharma Aims for Rs 1000 Crore Revenue

Lincoln Pharmaceuticals Ltd announces ambitious plan to achieve Rs 1000 crore revenue within three years through strategic expansion and new product launches. Read more about their growth strategy.

Granules India Gets USFDA Approval for Hyderabad Plant

Granules Life Sciences receives USFDA approval for new Hyderabad facility to manufacture diabetes drug Metformin HCL. Capacity: 10 billion tablets annually. Read more about this pharmaceutical milestone.

Sun Pharma: US Tariff Clarity & Q2 FY26 Outlook

Sun Pharma investors await Q2 FY26 results with cautious optimism as US tariff clarity emerges. Discover how import duties and market dynamics could impact India's pharmaceutical giant.

Curis Lifesciences IPO: 17x Subscription on Day 1

Curis Lifesciences' NSE SME IPO witnesses massive investor response with 17.36 times subscription on Day 1. Discover GMP trends, price band details, and why this pharma stock is creating buzz.

Trump: Deal Reached to Lower Weight Loss Drug Prices

Former President Donald Trump reveals groundbreaking agreement with pharmaceutical giants to dramatically reduce costs of popular weight loss medications, promising relief for millions struggling with obesity.

AstraZeneca Q3 Profit Jumps 77% to $2.53 Billion

British-Swedish pharma giant AstraZeneca reports blockbuster Q3 results with profits surging 77% to $2.53 billion, driven by robust cancer drug sales and strategic US market expansion.

Page 1 of 4